CoChat

Managing early-onset type 2 diabetes in the individual and at the population level

Open access

The DOI matches its Crossref record; 164 of the 169 references it cites were found in a registry or an index; none of the 151 sources its claims cite is checked for support yet.

Abstract

Early-onset type 2 diabetes (defined as type 2 diabetes diagnosed in people aged <40 years) is an increasingly prevalent condition with a more aggressive disease trajectory than late-onset type 2 diabetes. It is associated with accelerated microvascular and macrovascular complications, reduced life expectancy, and adverse pregnancy outcomes. Despite its rising incidence, global management strategies have mostly been extrapolated from studies in older adults with limited evidence specific to younger populations. In this Series paper, we aim to highlight the unique challenges in the management of early-onset type 2 diabetes and why current models of care are inadequate. We emphasise that early-onset type 2 diabetes necessitates proactive and combination treatment strategies to address weight, faster β-cell decline, worse insulin resistance, and rapidly progressing hyperglycaemia compared with late-onset type 2 diabetes. However, there is minimal evidence on how best to address these factors and clinical inertia risks contributing to glycaemic burden. Cardiovascular risk assessment tools underestimate long-term risk, contributing to low use of statin and antihypertensive therapy. Reproductive health remains a key concern, yet preconception and pregnancy care are inadequate, with low adherence to recommended interventions. Health-care systems are not optimised to address the distinct needs of young adults, and gaps in transitional care (from paediatric to adult services) contribute to disengagement and adverse outcomes. Addressing these challenges requires tailored management strategies that consider the unique metabolic and psychosocial factors in this population. In this Series paper, we summarise the evidence base for the management of early-onset type 2 diabetes, key evidence gaps, and discuss the multisectoral and transdisciplinary elements needed to achieve population-level prevention to reverse these concerning trends.

Overview

CoChat Summary

TL;DR

Early-onset type 2 diabetes (diagnosed <40 years) is rising globally and has a more aggressive course than late-onset disease, yet management and prevention strategies are largely extrapolated from older adults. This Lancet Series paper reviews the evidence and argues for proactive weight-focused, cardiovascular, reproductive, psychosocial, and multisectoral population-level approaches while highlighting major evidence gaps.

Key findings

  • Early-onset type 2 diabetes is associated with accelerated microvascular and macrovascular complications, reduced life expectancy (~15 years of life lost when diagnosed <30 years), and adverse pregnancy outcomes. Global prevalence in people aged 20–39 years rose from 2.9% (63 million) in 2013 to 3.8% (260 million) in 2021, and obesity is predicted to affect more than 206 million people aged 5–19 years by 2030.
  • Management should be weight-focused and proactive: early combination therapy reduced time-to-treatment failure by 48% in the VERIFY trial; metformin monotherapy is unlikely to achieve durable glycaemic control. Meta-analyses in children/adolescents showed SGLT-2 inhibitors reduced HbA1c (mean difference −0.93%; 95% CI −1.36 to −0.49) and GLP-1 receptor agonists reduced HbA1c (−1.01%; −1.26 to −0.76) and bodyweight (−1.6 kg; −2.83 to −0.36).
  • Bariatric surgery can induce remission in adolescents with severe obesity and type 2 diabetes: in TEEN-LABS (242 adolescents), remission was 95% at 3 years and 57% at 10 years; a systematic review of 29 studies (4970 adolescents) found 90% remission at 5 years and pooled BMI reduction of 13.1 kg/m² (95% CI 11.6–14.4).
  • Cardiovascular risk is underestimated, with a 3% increase in cardiovascular disease risk for every year earlier that type 2 diabetes is diagnosed under age 40 years; reproductive care is inadequate, and women with prior gestational diabetes have a 10-fold higher risk of progression to early-onset type 2 diabetes (HR 9.51; 95% CI 7.14–12.67). In LMICs, fewer than one in ten individuals receive guideline-based diabetes treatment.

Methods

  • This is a Lancet Series paper (narrative review/synthesis), not an original primary study. The authors conducted a literature search on PubMed from database inception to Jan 11, 2025, restricted to English-language articles.
  • Search terms included “type 2 diabetes”, “early-onset”, “youth-onset”, “management”, “prevention”, and “treatment”; the authors prioritised randomised controlled trials testing interventions, observational studies with glycaemic outcomes, and studies on prevention of obesity and type 2 diabetes in young people.
  • The paper summarises the evidence base, key evidence gaps, and multisectoral/transdisciplinary elements needed for population-level prevention and management.

Limitations

  • Stated in the text: young adults are substantially under-represented in diabetes research and clinical trials; evidence specific to early-onset type 2 diabetes is minimal; many recommendations have low GRADE certainty; there are no RCTs of statins specifically in early-onset type 2 diabetes; and long-term outcomes of bariatric surgery, GLP-1 receptor agonists on growth, and early cardiovascular/renal effects remain unclear.
  • Evident from the text: the literature search was restricted to PubMed and English-language articles, and the paper is a narrative Series review rather than a systematic review with formal risk-of-bias assessment or meta-analytic methods.
  • Evident from the text: the authors prioritised certain study designs and outcomes, which may introduce selection bias into the evidence summarised.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(25)01067-0

Cites

164 of 164 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Overlapping incidence and phenotype of early-onset type 2 diabetes, type 1 diabetes, and monogenic diabetes
Figure 1 Overlapping incidence and phenotype of early-onset type 2 diabetes, type 1 diabetes, and monogenic diabetesCC-BY · From the PDF
Figure 2 Key facets of management in early-onset type 2 diabetes in the individual
Figure 2 Key facets of management in early-onset type 2 diabetes in the individualCC-BY · From the PDF
Figure 3 The four phases of reproductive health to consider in women with early-onset type 2 diabetes
Figure 3 The four phases of reproductive health to consider in women with early-onset type 2 diabetesCC-BY · From the PDF

Verification

Claims the paper makes

0 Valid · 7 Not valid · 90 Not checked · 33 Own results and interpretations

54 more claims

Create a free account to see all 130 claims and to verify the 138 references still open.

See all claims — free account
  • It may state two separate claims as one. 56
  • Probably not a substantial claim. 21

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 164 references

Research works printed but not linked: 1

  1. 2021, Pregnancy outcomes in young women with youth-onset type 2 diabetes followed in the TODAY study, Diabetes Care, 45, 1038

Cited by

See all 47

Metadata

Authors
Misra, S., Khunti, K., Goyal, A., Gable, D., Armocida, B., Tandon, N., Sachdev, P., Wild, S. H., Hivert, M.-F., & Beran, D.
Affiliations
  • Imperial College Healthcare NHS Trust (GB)
  • University of Leicester (GB)
  • All India Institute of Medical Sciences Bhopal (IN)
  • Istituto Superiore di Sanità (IT)
  • All India Institute of Medical Sciences (IN)
  • University of Nottingham (GB)
  • University of Edinburgh (GB)
  • Harvard University (US)
  • University of Geneva (CH)
Corresponding author
Misra, Shivani
Venue
The Lancet
Publisher
Elsevier BV
Published
2025-06
Volume
405
Issue
10497
Pages
2341-2354
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4411538221
Cited by
47
References
169
Citations by year
2026: 40 · 2025: 7
FWCI
4.03
Type
journal article
Language
en
Open access
Locations
  • The Lancet (publishedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archive ouverte UNIGE (University of Geneva) (publishedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • Wellcome Trust
  • National Institute for Health Research Imperial Biomedical Research Centre
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
early-onset type 2 diabetes, young adults, diabetes management, combination therapy, insulin resistance, hyperglycemia, cardiovascular risk assessment, statin therapy, antihypertensive therapy, preconception care, pregnancy outcomes, reproductive health, transition to adult care, care transitions, population-level prevention, models of care
MeSH terms
Adult, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Pregnancy, Age of Onset

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Managing early-onset type 2 diabetes in the individual and at the population level. https://app.cochat.ai/papers/10.1016/s0140-6736(25)01067-0
The paper
Misra, S., Khunti, K., Goyal, A., Gable, D., Armocida, B., Tandon, N., Sachdev, P., Wild, S. H., Hivert, M.-F., & Beran, D. (2025). Managing early-onset type 2 diabetes in the individual and at the population level. The Lancet. https://doi.org/10.1016/s0140-6736(25)01067-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.